CoChat
Sign Up
Cited by 7Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

Protective mechanisms against Alzheimer's disease in APOE3‐Christchurch homozygous astrocytes

Open access
Tian, Xinran, Rivera, Erica Keane, Hwang, Inyoung, Nikitina, Arina A., Smith, Jennifer A., Cho, Youngsuh J., Sala‐Jarque, Julia, DuBose, Austin +3 more·2025·Alzheimer's & Dementia
DOI 10.1002/alz.70589PMC PMC12444642

Published version of a preprint

Open this paper in CoChat — free account

Abstract

INTRODUCTION: Alzheimer's disease (AD) is characterized by tau pathology, leading to neurodegeneration. Astrocytes regulate central nervous system homeostasis and influence AD progression. The APOE3‐Christchurch (APOE3‐Ch) variant is linked to AD resilience, but its protective mechanisms remain unclear. METHODS: Human induced pluripotent stem cell–derived astrocytes (APOE3‐Ch and wild type) were used to assess tau uptake, clearance, lipid metabolism, and transcriptomic adaptations. Fluorescently labeled 2N4R‐P301L tau oligomers were tracked, and pathway‐specific inhibitors dissected tau clearance mechanisms. Lipidomic and transcriptomic analyses were performed to identify genotype‐specific adaptations. RESULTS: APOE3‐Ch astrocytes exhibited enhanced tau uptake via heparan sulfate proteoglycan‐ and lipoprotein receptor‐related protein 1‐mediated pathways and superior clearance through lysosomal and proteasomal degradation. They exported less tau, limiting propagation. Transcriptomic analyses revealed upregulation of genes involved in cell projection assembly and endocytosis. Lipidomic profiling showed reduced ceramides and gamma‐linolenic acid, linked to decreased neuroinflammation and ferroptosis. DISCUSSION: APOE3‐Ch astrocytes promote tau clearance and metabolic adaptations, providing insights into genetic resilience in AD and potential therapeutic targets. Highlights: APOE3‐Christchurch (APOE3‐Ch) astrocytes exhibit significantly increased tau internalization compared to wild‐type astrocytes, facilitated by upregulated heparan sulfate proteoglycan and low‐density lipoprotein receptor‐related protein 1 pathways. APOE3‐Ch astrocytes demonstrate more efficient tau degradation via both lysosomal and proteasomal pathways, while exporting significantly less tau, potentially reducing tau propagation in the central nervous system. APOE3‐Ch astrocytes show upregulation of genes involved in cell projection assembly and endocytosis, suggesting structural and functional modifications that enhance tau processing. Lipidomic profiling reveals reduced ceramide levels and gamma‐linolenic acid downregulation in APOE3‐Ch astrocytes, alterations linked to reduced neuroinflammatory and ferroptotic activity, contributing to the protective phenotype.

AI snapshot

Written from the paper’s full text.

TL;DR

APOE3-Christchurch (APOE3-Ch) homozygous iPSC-derived astrocytes show enhanced tau oligomer uptake, faster degradation, and reduced tau export compared with wild-type astrocytes. They also have altered lipid metabolism, including lower ceramide levels and reduced apoE secretion, suggesting a complex protective phenotype in Alzheimer’s disease.

Key findings

  • APOE3-Ch astrocytes internalized more 2N4R-P301L tau oligomers than WT astrocytes, with increased reliance on HSPG-mediated uptake in addition to LRP1; HSPG-related genes including B3GAT1, EXT1, EXTL2, GPC3, HSPG2, NDST1, NDST3, SDC2, SULF1, SULF2, and XYLT1 were significantly upregulated.
  • APOE3-Ch astrocytes cleared intracellular tau more rapidly from 6 to 48 h after media change and exported less tau; total tau ELISA showed APOE3-Ch astrocytes decreased tau ≈2-fold after 24 h, whereas WT did not change significantly.
  • Lysosomal and proteasomal degradation both contributed to tau clearance; BafA1 partially inhibited clearance in APOE3-Ch astrocytes, while MG132 halted clearance in both genotypes.
  • Lipidomic profiling found significantly reduced ceramides, including Cer(14:0), Cer(16:0), Cer(18:0), Cer(18:1), Cer(20:0), Cer(20:1), and DCERs in pellets, and Cer(16:0), Cer(18:0), Cer(22:0) in media; ceramide catabolism genes ACER1, ASAH1, SGMS1, SGMS2, and SPHK1 were upregulated. APOE3-Ch astrocytes also had lower extracellular apoE and more lipid droplets after oleic acid treatment.

Methods

  • Human iPSC-derived astrocytes from one WT parental line (KOLF2.1J) and two homozygous APOE3-Ch lines (1262 and 1264) were differentiated and used for functional assays.
  • Tau handling was assessed with fluorescently labeled 2N4R-P301L tau oligomers, flow cytometry, heparin and RAP competition, lysosomal/proteasomal inhibitors (BafA1, MG132), colocalization with LAMP1, LC3B, P62, and 20S proteasome, and total tau ELISA.
  • Lipid metabolism was assessed by lipid droplet induction/quantification, apoE ELISA, and targeted lipidomics; transcriptomic profiling used RNA sequencing with DESeq2, GSEA, and pathway analysis under basal and tau-treated conditions.

Limitations

  • The paper states that iPSC-derived astrocytes may not fully replicate mature in vivo astrocytes; low AQP4 expression suggests incomplete maturation, and validation in more mature or in vivo systems is needed.
  • The paper notes technical limitations: variability in WT astrocytes at the 0 h clearance time point, a small effect size for BafA1 in APOE3-Ch astrocytes, and unresolved mechanisms for reduced apoE export.
  • The text makes evident that findings rely on one WT line and two APOE3-Ch clones, with clonal variability acknowledged; the study also does not address whether HSPGs and LRP1 cooperate directly or which specific endocytosis pathways mediate tau uptake.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1002/alz.70589

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

33 of 46 cited sources checked · 18 supported · 3 flagged · accuracy not yet measured

  • Premisecitation

    Astrocytes are active participants in tau clearance, a process critical for limiting the spread of pathological tau aggregates in AD and related tauopathies.

    “astrocytes are increasingly recognized as active participants in tau clearance, a process critical for limiting the spread of pathological tau aggregates in AD and related tauopathies.”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [11] Fleeman RM, Proctor EA. Astrocytic propagation of Tau in the context of Alzheimer's disease. Front Cell Neurosci. 2021; 15: 645233. doi: 10.3389/fncel.2021.645233 33815065 PMC8010320 source
    • cites [12] Martini‐Stoica H, Cole AL, Swartzlander DB, et al. TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J Exp Med. 2018; 215: 2355‐ 2377. doi: 10.1084/jem.20172158 30108137 PMC6122971 source
    • cites [13] Perea JR, López E, Díez‐Ballesteros JC, Ávila J, Hernández F, Bolós M. Extracellular monomeric Tau is internalized by astrocytes. Front Neurosci. 2019; 13: 442. doi: 10.3389/fnins.2019.00442 31118883 PMC6504834 source

      The Results show that cultured astrocytes internalize extracellular monomeric tau. But the Discussion says this finding supports glial contribution to cell-to-cell tau propagation, not clearance that limits the spread of pathological aggregates. The paper does not demonstrate that astrocyte uptake reduces spread in AD or related tauopathies. (LLM, conf=0.87)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
  • Premisecitation

    Increased levels of Cer16, Cer18, Cer20, and Cer24 are found in the brains of patients with Alzheimer's disease.

    “Specifically, increased levels of Cer16, Cer18, Cer20, and Cer24 are found in the brains from patients with AD. 26”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [26] Filippov V, Song MA, Zhang K, et al. Increased ceramide in brains with Alzheimer's and other neurodegenerative diseases. J Alzheimers Dis JAD. 2012; 29: 537‐ 547. doi: 10.3233/JAD-2011-111202 22258513 PMC3643694 source
  • Interpretationown data

    Decreased secreted tau in APOE3-Ch astrocytes may contribute to limited tau spread in the human case expressing the Christchurch variant.

    “This decrease in secreted tau in APOE3‐Ch astrocytes may contribute to the limited tau spread in the human case expressing the Christchurch variant. 10”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [10] Sepulveda‐Falla D, Sanchez JS, Almeida MC, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol (Berl). 2022; 144: 589‐ 601. doi: 10.1007/s00401-022-02467-8 35838824 PMC9381462 source
  • Premisecitation

    Elevated ceramide levels have been associated with Alzheimer's disease pathology, including promoting Aβ accumulation, mitochondrial dysfunction, and inflammation.

    “Elevated Cer levels have been associated with AD pathology, including promoting Aβ accumulation, mitochondrial dysfunction, and inflammation. 24 , 25”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [24] Chowdhury MR, Jin HK, Bae J. Diverse roles of ceramide in the progression and pathogenesis of Alzheimer's disease. Biomedicines. 2022; 10: 1956. doi: 10.3390/biomedicines10081956 36009503 PMC9406151 source
    • cites [25] Jazvinšćak Jembrek M, Hof PR, Šimić G. Ceramides in Alzheimer's disease: key mediators of neuronal apoptosis induced by oxidative stress and Aβ accumulation. Oxid Med Cell Longev. 2015; 2015: 346783. doi: 10.1155/2015/346783 26090071 PMC4458271 source

      Section 2 reports elevated ceramide levels in AD, and the Conclusions link ceramides to Aβ accumulation and mitochondrial dysfunction. Section 4, “Ceramides and Inflammation,” links ceramide production to inflammatory mediators, but describes those mediators as stimulating ceramide production rather than establishing that elevated ceramides promote inflammation. No page numbers are available in our copy. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
  • Premisecitation

    Patient studies show limited tau pathology in the individual carrying the APOE3-Ch variant and the familial Alzheimer's disease mutation PSEN1-E280A.

    “Based on patient studies showing limited tau pathology in the individual carrying the APOE3‐Ch variant and the familial AD mutation PSEN1‐E280A, 6 we hypothesized that the APOE3‐Ch variant enhances astrocytic tau clearance and thereby limits tau spread in the brain.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [6] Arboleda‐Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019; 25: 1680‐ 1683. doi: 10.1038/s41591-019-0611-3 31686034 PMC6898984 source
  • Classified as probably not a substantial claim. 29
  • May combine two claims. 44
  • The quote only partly states this claim. 4

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Astrocyte cell projections are critical for cellular communication and for the clearance of toxic oligomers such as tau.

    “Astrocyte cell projections, or extensions, are critical for cellular communication 29 and for the clearance of toxic oligomers such as tau. 30”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [29] Vasile F, Dossi E, Rouach N. Human astrocytes: structure and functions in the healthy brain. Brain Struct Funct. 2017; 222: 2017‐ 2029. doi: 10.1007/s00429-017-1383-5 28280934 PMC5504258 source

      The source supports the communication portion, to which citation 29 is attached: its Interlaminar astroglia section describes a possible role for astrocyte projections in long-distance communication. It also says their functional significance is undetermined, so calling them “critical” overstates the evidence. The tau-clearance portion has a separate citation (30) and is not attributed to this source here. (LLM, conf=0.85)

      Experimental — accuracy not yet measured
    • cites [30] Mothes T, Portal B, Konstantinidis E, et al. Astrocytic uptake of neuronal corpses promotes cell‐to‐cell spreading of tau pathology. Acta Neuropathol Commun. 2023; 11: 97. doi: 10.1186/s40478-023-01589-8 37330529 PMC10276914 source

      Citation 30 is attached to the claim that astrocyte extensions clear toxic tau. The Discussion says astrocytes are unable to clear engulfed tau aggregates; instead, ineffective degradation promotes the cell-to-cell spread of pathological tau. The paper therefore makes the contrary point about clearance. (LLM, conf=0.89)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Previous studies have shown that astrocytes can internalize tau monomers, truncated pre-formed fibrils (PFFs), and tau oligomers through HSPG-independent mechanisms.

    “Previous studies have shown that astrocytes can internalize tau monomers, 13 truncated pre‐formed fibrils (PFFs), 12 and tau oligomers 11 , 41 through HSPG‐independent mechanisms. 28”
    Quote in the paperNot a substantial claim2 of 3 sources checked
    • cites [11] Fleeman RM, Proctor EA. Astrocytic propagation of Tau in the context of Alzheimer's disease. Front Cell Neurosci. 2021; 15: 645233. doi: 10.3389/fncel.2021.645233 33815065 PMC8010320 source

      The “Tau Internalization In Astrocytes” section reports uptake of tau monomers, truncated PFFs, and aggregates, and explicitly describes monomer uptake as non-HSPG-mediated. It describes PFF uptake by phagocytosis but does not establish that PFF or oligomer uptake is HSPG-independent; it also does not specifically identify the aggregates as oligomers. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [12] Martini‐Stoica H, Cole AL, Swartzlander DB, et al. TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. J Exp Med. 2018; 215: 2355‐ 2377. doi: 10.1084/jem.20172158 30108137 PMC6122971 source

      Citation 28 is attached to the claim that uptake occurs through HSPG-independent mechanisms. The Results section (page not available in our copy) says instead that tau fibril uptake involves interaction with cell-surface HSPGs and reports that heparin, used to inhibit that interaction, reduces fibril uptake in primary astrocytes. (LLM, conf=0.88)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
    • cites 13, 28, 41? no, exactly as written: 11, 12, 13, 28, 41

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Premisecitation

    APOE3-Ch has been associated with reduced Alzheimer's disease risk and neuroprotection in individuals carrying high-risk genetic mutations for AD.

    “APOE3‐Ch has been associated with reduced Alzheimer's disease (AD) risk and neuroprotection in individuals carrying high‐risk genetic mutations for AD.”
    Quote in the paperSubstantial claim2 of 3 sources checked
    • cites [6] Arboleda‐Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019; 25: 1680‐ 1683. doi: 10.1038/s41591-019-0611-3 31686034 PMC6898984 source

      The Abstract reports one PSEN1 E280A mutation carrier homozygous for APOE3-Christchurch who developed impairment decades later than expected and had limited tau pathology and neurodegeneration. This supports an association with delayed clinical onset and possible neuroprotection, but the case report does not establish reduced AD risk across individuals carrying high-risk mutations. (LLM, conf=0.87)

      Experimental — accuracy not yet measured
    • cites [7] Nelson MR, Liu P, Agrawal A, et al. The APOE‐R136S mutation protects against APOE4‐driven Tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023; 26: 2104‐ 2121. doi: 10.1038/s41593-023-01480-8 37957317 PMC10689245 source
    • cites [8] Chen Y, Song S, Parhizkar S, et al. APOE3ch alters microglial response and suppresses Aβ‐induced tau seeding and spread. Cell. 2024; 187: 428‐ 445.e20. doi: 10.1016/j.cell.2023.11.029 38086389 PMC10842861 source

  • Classified as probably not a substantial claim.

    Premisecitation

    Pathological tau disrupts synaptic integrity and neuronal connectivity, driving neurodegeneration and cognitive decline.

    “Pathological tau, characterized by hyperphosphorylation and aggregation into neurofibrillary tangles, disrupts synaptic integrity and neuronal connectivity, driving neurodegeneration and cognitive decline.”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [14] Goedert M, Eisenberg DS, Crowther RA. Propagation of Tau aggregates and neurodegeneration. Annu Rev Neurosci. 2017; 40: 189‐ 210. doi: 10.1146/ANNUREV-NEURO-072116-031153 28772101 source

      The Introduction (page not provided) identifies tau dysfunction as a cause of neurodegeneration, and Tau Toxicity reports synaptic-protein missorting and nerve-cell dysfunction in a mouse model. But Propagation of Tau Aggregates describes synaptic contacts and neuronal connectivity as routes for tau spread, not as structures that tau disrupts. The cited passages also do not establish the proposed chain from disrupted connectivity to cognitive decline. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites [15] Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol (Berl). 2017; 133: 665‐ 704. doi: 10.1007/s00401-017-1707-9 28386764 PMC5390006 source

      In “Tau-mediated neurodegeneration > Axonal transport impairment in the tauopathies” (page unavailable), the review says pathological tau can compromise synapses and contribute to synaptic degeneration and neuronal demise. But “Tauopathies > Tau in neurofibrillary tangles and amyloid pathology” cautions that cognitive decline is not an inevitable result of tau pathology and that the mechanism linking synapse loss to cognitive decline is unidentified. The claim overstates a definite causal chain from pathological tau through disrupted connectivity to cognitive decline. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Astrocytes are critical for maintaining CNS homeostasis, playing essential roles in lipid metabolism and clearance of toxic protein aggregates.

    “Astrocytes are critical for maintaining central nervous system (CNS) homeostasis, playing essential roles in lipid metabolism and the clearance of toxic protein aggregates.”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites [1] Ioannou MS, Jackson J, Sheu S‐H, et al. Neuron‐Astrocyte metabolic coupling protects against activity‐induced fatty acid toxicity. Cell. 2019; 177: 1522‐ 1535.e14. doi: 10.1016/j.cell.2019.04.001 31130380 source
    • cites [2] Blumenfeld J, Yip O, Kim MJ, Huang Y. Cell type‐specific roles of APOE4 in Alzheimer disease. Nat Rev Neurosci. 2024; 25: 91‐ 110. doi: 10.1038/s41583-023-00776-9 38191720 PMC11073858 source

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    apoE facilitates cholesterol transport, extracellular amyloid beta clearance, synaptic pruning, and blood-brain barrier integrity.

    “apolipoprotein E (apoE), a lipid‐binding protein expressed by astrocytes, which facilitates cholesterol transport, extracellular amyloid beta (Aβ) clearance, synaptic pruning, and blood–brain barrier (BBB) integrity.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [2] Blumenfeld J, Yip O, Kim MJ, Huang Y. Cell type‐specific roles of APOE4 in Alzheimer disease. Nat Rev Neurosci. 2024; 25: 91‐ 110. doi: 10.1038/s41583-023-00776-9 38191720 PMC11073858 source

  • Classified as probably not a substantial claim. May combine two claims.

    Premisecitation

    Ceramides are bioactive sphingolipids involved in cell signaling, apoptosis, and membrane structure, and play a critical role in neurodegenerative diseases like Alzheimer's disease.

    “Cers are bioactive sphingolipids involved in cell signaling, apoptosis, and membrane structure, playing a critical role in neurodegenerative diseases like AD. 22 , 23”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [22] Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. J Lipid Res. 2009; 50: S91‐ S96. doi: 10.1194/jlr.R800080-JLR200 19017611 PMC2674734 source

      The Abstract identifies ceramide as a bioactive sphingolipid and describes sphingolipids’ roles in membrane structure and signaling. “SLs as Bioactive Molecules” links ceramide signaling to apoptosis. But “Inducers of SL Enzymes” says ceramide has been linked to Alzheimer’s disease and neurodegeneration and may mediate an amyloid-β response; it does not establish the claimed critical role. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • cites [23] Lee JY, Jin HK, Bae J. Sphingolipids in neuroinflammation: a potential target for diagnosis and therapy. BMB Rep. 2020; 53: 28‐ 34. doi: 10.5483/BMBRep.2020.53.1.278 31818364 PMC6999823 source

      The Ceramide section describes ceramide’s effects on neuronal cell death, apoptosis, and inflammatory signaling. The Alzheimer’s disease section links altered ceramide levels and metabolism to AD pathogenesis. The cited passages do not establish the claimed role of ceramides in membrane structure. (LLM, conf=0.82)

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim.

    Premisecitation

    Dihomo-gamma-linolenic acid, a metabolite of gamma-linolenic acid, has been implicated in inducing ferroptosis-mediated neurodegeneration, particularly in dopaminergic neurons.

    “Notably, dihomo‐gamma‐linolenic acid (DGLA), a metabolite of the polyunsaturated FA GLA, has been implicated in inducing ferroptosis‐mediated neurodegeneration, particularly in dopaminergic neurons. 27”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [27] Sarparast M, Pourmand E, Hinman J, et al. Dihydroxy‐Metabolites of Dihomo‐γ‐linolenic acid drive ferroptosis‐mediated neurodegeneration. ACS Cent Sci. 2023; 9: 870‐ 882. doi: 10.1021/acscentsci.3c00052 37252355 PMC10214511 source

      The Results and Conclusion report that DGLA treatment triggers neurodegeneration predominantly in dopaminergic neurons of C. elegans, with ferroptosis implicated particularly at early stages. Our copy does not establish the claim’s additional description of DGLA as a metabolite of GLA (searched for GLA and its conversion to DGLA). (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    RIN1 and PLD2 have been implicated in activating receptor-mediated endocytosis, RAB7B in late endosomes, and CD81 in exosomes and multivesicular bodies.

    “For instance, RIN1 and PLD2 have been implicated in activating receptor‐mediated endocytosis, 31 , 32 RAB7B in late endosomes, 33 , 34 and CD81 in exosomes and multivesicular bodies (MVBs). 35”
    Quote in the paperNot a substantial claim1 of 3 sources checked
    • cites [31] Tall GG, Barbieri MA, Stahl PD, Horazdovsky BF. Ras‐activated endocytosis is mediated by the Rab5 guanine nucleotide exchange activity of RIN1. Dev Cell. 2001; 1: 73‐ 82. doi: 10.1016/s1534-5807(01)00008-9 11703925 source
    • cites [32] Donaldson JG. Phospholipase D in endocytosis and endosomal recycling pathways. Biochim Biophys Acta. 2009; 1791: 845‐ 849. doi: 10.1016/j.bbalip.2009.05.011 19540357 PMC2731818

      Not checked in the free run.

    • cites 33, 34? no, exactly as written: 31, 32, 33, 34, 35

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Astrocytes can internalize both tau monomers and higher-molecular-weight tau species.

    “Previous studies have demonstrated that astrocytes can internalize both tau monomers and higher‐molecular‐weight tau species. 13 , 28”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites [13] Perea JR, López E, Díez‐Ballesteros JC, Ávila J, Hernández F, Bolós M. Extracellular monomeric Tau is internalized by astrocytes. Front Neurosci. 2019; 13: 442. doi: 10.3389/fnins.2019.00442 31118883 PMC6504834 source
    • cites [28] Wang P, Ye Y. Filamentous recombinant human Tau activates primary astrocytes via an integrin receptor complex. Nat Commun. 2021; 12: 95. doi: 10.1038/s41467-020-20322-w 33398028 PMC7782792 source

      The Results section, “HSPG-independent uptake of Tau PFFs by primary astrocytes,” reports efficient internalization of tau fibrils by primary astrocytes. It says the cells were also treated with monomeric tau, but does not report that they internalized it. The Introduction broadly mentions uptake of different tau species by neurons, microglia, and astrocytes without establishing monomer uptake specifically in astrocytes. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim.

    Premisecitation

    Functional diversity of APOE isoforms profoundly impacts astrocyte biology.

    “The functional diversity of APOE isoforms profoundly impacts astrocyte biology.”
    Quote in the paperSubstantial claim3 of 3 sources checked
    • cites [3] de Leeuw SM, Kirschner AW, Lindner K, et al. APOE2, E3, and E4 differentially modulate cellular homeostasis, cholesterol metabolism, and inflammatory response in isogenic iPSC‐derived astrocytes. Stem Cell Rep. 2021; 17: 110. doi: 10.1016/j.stemcr.2021.11.007 PMC8758949 34919811 source
    • cites [4] Lindner K, Beckenbauer K, van Ek LC, et al. Isoform‐ and cell‐state‐specific lipidation of ApoE in astrocytes. Cell Rep. 2022; 38: 110435. doi: 10.1016/j.celrep.2022.110435 35235798 source
    • cites [5] Serrano‐Pozo A, Das S, Hyman BT. APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol. 2021; 20: 68‐ 80. doi: 10.1016/S1474-4422(20)30412-9 33340485 PMC8096522 source

  • Classified as probably not a substantial claim.

    Premisecitation

    Ceramides are known to initiate some of the pathological changes that drive AD progression.

    “Ceramides are also known to initiate some of the pathological changes that drive AD progression. 24 , 25”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites [24] Chowdhury MR, Jin HK, Bae J. Diverse roles of ceramide in the progression and pathogenesis of Alzheimer's disease. Biomedicines. 2022; 10: 1956. doi: 10.3390/biomedicines10081956 36009503 PMC9406151 source
    • cites [25] Jazvinšćak Jembrek M, Hof PR, Šimić G. Ceramides in Alzheimer's disease: key mediators of neuronal apoptosis induced by oxidative stress and Aβ accumulation. Oxid Med Cell Longev. 2015; 2015: 346783. doi: 10.1155/2015/346783 26090071 PMC4458271 source

  • May combine two claims.

    Interpretationcitation

    Accumulation of unsaturated TGs in APOE ε4 astrocytes may promote oxidative stress and pro-inflammatory profiles, contributing to neuroinflammation and neurotoxicity, processes not observed in APOE3-Ch astrocytes.

    “The accumulation of unsaturated TGs in APOE ε4 astrocytes may promote oxidative stress and pro‐inflammatory profiles, contributing to neuroinflammation and neurotoxicity, 38 processes that are not observed in APOE3‐Ch astrocytes.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [38] Windham IA, Powers AE, Ragusa JV, et al. APOE traffics to astrocyte lipid droplets and modulates triglyceride saturation and droplet size. J Cell Biol. 2024; 223: e202305003. doi: 10.1083/jcb.202305003 38334983 PMC10857907 source

      The Discussion (page not provided) reports unsaturated triglyceride accumulation and increased lipid-peroxidation sensitivity in APOE4 astrocyte droplets, and proposes that these changes could lead to a proinflammatory state preceding neurodegeneration. The paper does not establish the proposed neuroinflammation or neurotoxicity, and it does not address whether these processes are absent in APOE3-Ch astrocytes. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • Classified as probably not a substantial claim.

    Premisecitation

    Ceramides are bioactive lipids that play a significant role in several pathological processes associated with AD, including Aβ plaque formation, mitochondrial dysfunction, cellular senescence, and autophagy dysfunction.

    “Ceramides are bioactive lipids that play a significant role in several pathological processes associated with AD, including Aβ plaque formation, mitochondrial dysfunction, cellular senescence, and autophagy dysfunction. 24”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites [24] Chowdhury MR, Jin HK, Bae J. Diverse roles of ceramide in the progression and pathogenesis of Alzheimer's disease. Biomedicines. 2022; 10: 1956. doi: 10.3390/biomedicines10081956 36009503 PMC9406151 source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Selective removal of astrocytic APOE ε4 strongly protects against tau-induced synaptic loss and reduces microglial-mediated synaptic phagocytosis.

    “The role of astrocytic APOE in tau‐mediated neurodegeneration has been highlighted by recent work showing that selective removal of astrocytic APOE ε4 strongly protects against tau‐induced synaptic loss and reduces microglial‐mediated synaptic phagocytosis. 40”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites [40] Wang C, Xiong M, Gratuze M, et al. Selective removal of astrocytic APOE4 strongly protects against tau‐mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 2021; 109: 1657‐ 1674.e7. doi: 10.1016/j.neuron.2021.03.024 33831349 PMC8141024 source

  • The quote only partly states this claim.

    Findingown data

    APOE3-Ch astrocytes export less tau than wild-type astrocytes.

    “They exported less tau, limiting propagation.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: iPSC-derived astrocytes recapitulate the relevant properties of human astrocytes in vivo.
    • Rests on an assumption: The 2N4R-P301L tau oligomers used are representative of pathological tau species in AD.
    • Rests on an assumption: The WT line (KOLF2.1J) is a valid control for APOE3-Ch lines.

  • The quote only partly states this claim.

    Findingown data

    APOE3-Ch astrocytes exhibit superior tau clearance through lysosomal degradation.

    “APOE3‐Ch astrocytes demonstrate more efficient tau degradation via both lysosomal and proteasomal pathways”
    Quote in the paperSubstantial claim
    • Rests on an assumption: iPSC-derived astrocytes recapitulate the relevant properties of human astrocytes in vivo.
    • Rests on an assumption: The 2N4R-P301L tau oligomers used are representative of pathological tau species in AD.
    • Rests on an assumption: The WT line (KOLF2.1J) is a valid control for APOE3-Ch lines.

  • The quote only partly states this claim.

    Findingown data

    APOE3-Ch astrocytes exhibit superior tau clearance through proteasomal degradation.

    “APOE3‐Ch astrocytes demonstrate more efficient tau degradation via both lysosomal and proteasomal pathways”
    Quote in the paperSubstantial claim
    • Rests on an assumption: iPSC-derived astrocytes recapitulate the relevant properties of human astrocytes in vivo.
    • Rests on an assumption: The 2N4R-P301L tau oligomers used are representative of pathological tau species in AD.
    • Rests on an assumption: The WT line (KOLF2.1J) is a valid control for APOE3-Ch lines.

  • May combine two claims.

    Findingown data

    After tau internalization, APOE3-Ch astrocytes degrade tau through both lysosomal and proteasomal pathways, while WT astrocytes primarily rely on proteasomal degradation and secrete more tau.

    “After tau internalization, APOE3‐Ch astrocytes degraded tau through both lysosomal and proteasomal pathways, while WT astrocytes primarily relied on proteasomal degradation and secreted more tau than APOE3‐Ch astrocytes.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingown data

    In the intracellular neutral lipid panel, cholesterol esters, ceramides, diacylglycerols, and triglycerides were the more abundant lipid classes overall, while dihydroceramides and monoacylglycerols exhibited lower abundances.

    “The intracellular neutral lipid panel revealed that cholesterol esters (CEs), ceramides (Cer), diacylglycerols (DAGs), and TGs were the more abundant lipid classes overall, while dihydroceramides (DCERs) and monoacylglycerols (MGs) exhibited lower abundances (Figure 2A).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    In the genotype-treatment interaction, upon tau treatment, APOE3-Ch astrocytes upregulate genes involved in cell projection assembly, while WT astrocytes downregulate this process and upregulate cell cycle-related genes.

    “This interaction analysis revealed that, upon tau treatment, APOE3‐Ch astrocytes upregulate genes involved in cell projection assembly, while WT astrocytes showed downregulation in this process, along with concurrent upregulation of cell cycle–related genes.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    The neuronal marker MAP2 is absent in iPSCs and shows only faint signal in astrocyte cultures.

    “The neuronal marker MAP2 was absent in iPSCs and showed only faint signal in astrocyte cultures, suggesting minimal neuronal contamination.”
    Quote in the paperNot a substantial claim

  • The quote only partly states this claim.

    Findingown data

    Genes associated with the endocytosis pathway, including RIN1, RAB7B, PLD2, MYD88, MFGE8, MAPKAPK3, LETMD1, EEF2K, CHRNA7, CD81, and ANK2, follow a similar pattern of downregulation in tau-treated WT and upregulation in tau-treated APOE3-Ch astrocytes.

    “In parallel, genes associated with the endocytosis pathway, such as RIN1, RAB7B, PLD2, MYD88, MFGE8, MAPKAPK3, LETMD1, EEF2K, CHRNA7, CD81, and ANK2, also followed a similar pattern (Figure 5G).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    During the first 12 hours post media change, APOE3-Ch astrocytes exhibited a faster clearance rate compared with WT astrocytes, while the opposite was observed from 12 to 48 hours.

    “During the first 12 hours post media change, APOE3‐Ch astrocytes exhibited a faster clearance rate compared to WT astrocytes, while the opposite was observed from 12 to 48 hours (Figure S5B,C).”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Findingown data

    In the polar lipid panel, intracellularly, the most abundant lipids in both WT and APOE3-Ch astrocytes were phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol, and phosphatidylserine, with no significant differences in total abundance between genotypes.

    “In the polar lipid panel, intracellularly, the most abundant lipids in both WT and APOE3‐Ch astrocytes were phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), with no significant differences in total abundance between genotypes (Figure S2A).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    APOE3-Ch astrocytes internalize tau oligomers more efficiently than WT astrocytes, mediated by both HSPG and LRP1 pathways.

    “Our analysis of tau uptake demonstrated that APOE3‐Ch astrocytes internalize tau oligomers more efficiently than WT astrocytes, a process mediated by both HSPG and LRP1 pathways.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Transcriptomic analysis showed upregulation of cell projection and endocytic pathways in APOE3-Ch astrocytes, the latter potentially enhancing their ability to internalize and degrade tau oligomers.

    “Finally, transcriptomic analysis showed upregulation of cell projection and endocytic pathways in APOE3‐Ch astrocytes, the latter potentially enhancing their ability to internalize and degrade tau oligomers.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    Several phosphatidylethanolamine species were notably decreased, while several phosphatidylserine species were increased in APOE3-Ch astrocytes.

    “However, several PE species were notably decreased, while several PS species were increased in APOE3‐Ch astrocytes (Figure 2B,C).”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Findingown data

    After tau internalization, APOE3-Ch astrocytes degrade tau primarily through lysosomal and proteasomal pathways, with lysosomal degradation playing a particularly vital role.

    “After tau internalization, our data show that APOE3‐Ch astrocytes degrade tau primarily through lysosomal and proteasomal pathways, with lysosomal degradation playing a particularly vital role.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    APOE3-Ch astrocytes show enhanced tau internalization and intracellular degradation via lysosomal and proteasomal pathways, along with reduced extracellular tau accumulation.

    “Specifically, we observed enhanced tau internalization and intracellular degradation via lysosomal and proteasomal pathways, along with reduced extracellular tau accumulation.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    WT astrocytes rely more heavily on proteasomal degradation and secrete a greater proportion of tau than APOE3-Ch astrocytes.

    “In contrast, WT astrocytes rely more heavily on proteasomal degradation and secrete a greater proportion of tau.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Findingown data

    APOE3-Ch astrocytes use both HSPG- and LRP1-mediated pathways for tau oligomer internalization, while WT astrocytes primarily rely on LRP1-mediated tau uptake.

    “Our data suggest that, like neurons, which rely heavily on LRP1‐mediated and HSPG‐mediated uptake, 20 , 42 , 43 APOE3‐Ch astrocytes use both HSPG‐ and LRP1‐mediated pathways for tau oligomer internalization, while WT astrocytes primarily rely on LRP1‐mediated tau uptake.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    APOE3-Ch astrocytes promote tau clearance and metabolic adaptations, providing insights into genetic resilience in AD.

    “APOE3‐Ch astrocytes promote tau clearance and metabolic adaptations, providing insights into genetic resilience in AD and potential therapeutic targets.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The two APOE3-Ch iPSC lines (1262 and 1264) are equivalent and can be combined to represent a single genotype.
    • Rests on an assumption: iPSC-derived astrocytes recapitulate the relevant properties of human astrocytes in vivo.
    • Rests on an assumption: The 2N4R-P301L tau oligomers used are representative of pathological tau species in AD.
    • Rests on an assumption: The WT line (KOLF2.1J) is a valid control for APOE3-Ch lines.
    • Rests on an assumption: The mechanisms by which APOE3-Ch confers protection against AD are poorly understood.

  • May combine two claims.

    Interpretationown data

    APOE3-Ch astrocytes upregulate endocytosis genes upon tau treatment, suggesting enhancement of endocytosis and subsequent lysosomal degradation pathways.

    “APOE3‐Ch astrocytes upregulated these genes upon tau treatment, suggesting an enhancement of endocytosis and subsequent lysosomal degradation pathways.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    RNA sequencing was performed with three biological replicates for each cell line (WT, 1262, 1264).

    “Three biological replicates were prepared for each cell line, including three replicates for WT astrocytes and three replicates each for the 1262 and 1264 cell lines.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    This differential tau uptake reflects an intrinsic characteristic of APOE3-Ch astrocytes, potentially contributing to their protective role against Alzheimer's disease.

    “This differential uptake reflects an intrinsic characteristic of APOE3‐Ch astrocytes, potentially contributing to their protective role against AD.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    Lipidomics was performed with four biological replicates for each cell line (WT, 1262, 1264).

    “Four biological replicates were prepared for each cell line, including four replicates for WT astrocytes and four replicates each for the 1262 and 1264 cell lines.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationown data

    Transcriptomic analysis reveals a complex and coordinated defense mechanism in APOE3-Ch astrocytes in response to tau pathology, involving upregulation of cell projections and endocytosis pathways, facilitating enhanced uptake and degradation of tau, which may confer protective effects against tau toxicity.

    “In summary, our transcriptomic analysis reveals a complex and coordinated defense mechanism in APOE3‐Ch astrocytes in response to tau pathology. This involves upregulation of cell projections and endocytosis pathways, facilitating enhanced uptake and degradation of tau, which may confer protective effects against tau toxicity.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductnone given

    All experiments were conducted in biological triplicate or quadruplicate to ensure robustness and reproducibility.

    “All experiments were conducted in biological triplicate or quadruplicate to ensure robustness and reproducibility.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationown data

    Transcriptional changes align with cellular assay findings and suggest APOE3-Ch astrocytes have a heightened capacity for clearing tau.

    “These transcriptional changes align with our cellular assay findings and suggest that APOE3‐Ch astrocytes have a heightened capacity for clearing tau.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductreasoning

    Puncta with a signal-to-noise ratio < 1% were excluded to remove low-quality detections in lipid droplet quantification.

    “puncta with a signal‐to‐noise ratio < 1% were excluded to remove low‐quality detections.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    Reduced AQP4 expression may alter water and ion homeostasis in these cells.

    “Reduced AQP4 expression may alter water and ion homeostasis in these cells.”
    Quote in the paperNot a substantial claim

  • Classified as probably not a substantial claim.

    Premisecitation

    APOE ε4 impairs tau uptake and trafficking, potentially exacerbating tau pathology.

    “The efficiency of tau processing is influenced by APOE isoforms, with APOE ε4 impairing tau uptake and trafficking, potentially exacerbating tau pathology.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [16] Eisenbaum M, Pearson A, Ortiz C, et al. ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Glia. 2024; 72: 184‐ 205. doi: 10.1002/glia.24469 37668005 source

  • May combine two claims.

    Premisecitation

    APOE3-Ch mice have exhibited peripheral dyslipidemia, including elevated APOE and APOB levels, as well as increased association of APOE with VLDL and low-density lipoproteins LDL.

    “APOE3‐Ch mice have exhibited peripheral dyslipidemia, including elevated APOE and APOB levels, as well as increased association of APOE with VLDL and low‐density lipoproteins LDL. 8”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [8] Chen Y, Song S, Parhizkar S, et al. APOE3ch alters microglial response and suppresses Aβ‐induced tau seeding and spread. Cell. 2024; 187: 428‐ 445.e20. doi: 10.1016/j.cell.2023.11.029 38086389 PMC10842861 source

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    APOE3-Ch is a rare genetic variant of APOE and has been associated with HLPP3 in patients.

    “APOE3‐Ch is a rare genetic variant of APOE and has been associated with HLPP3 in patients. 21”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [21] Koopal C, Marais AD, Westerink J, Visseren FLJ. Autosomal dominant familial dysbetalipoproteinemia: a pathophysiological framework and practical approach to diagnosis and therapy. J Clin Lipidol. 2017; 11: 12‐ 23.e1. doi: 10.1016/j.jacl.2016.10.001 28391878 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    In the CNS, apoE facilitates the transport of cholesterol and fatty acids between cells, maintaining lipid homeostasis.

    “In the CNS, apoE facilitates the transport of cholesterol and FAs between cells, maintaining lipid homeostasis.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [1] Ioannou MS, Jackson J, Sheu S‐H, et al. Neuron‐Astrocyte metabolic coupling protects against activity‐induced fatty acid toxicity. Cell. 2019; 177: 1522‐ 1535.e14. doi: 10.1016/j.cell.2019.04.001 31130380 source

  • May combine two claims.

    Interpretationreasoning

    This lipid dyshomeostasis may induce lipotoxicity and disrupt metabolic coupling between astrocytes and neurons.

    “This lipid dyshomeostasis may induce lipotoxicity and disrupt metabolic coupling between astrocytes and neurons.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    APOE3-Ch astrocytes enhance their ability to form projections, possibly to aid in the clearance of tau oligomers.

    “In contrast, these genes were upregulated in APOE3‐Ch astrocytes after tau treatment, suggesting that APOE3‐Ch astrocytes enhance their ability to form projections, possibly to aid in the clearance of tau oligomers.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    The astrocyte cultures are largely astrocytic and have undergone appropriate lineage restriction.

    “These staining results confirm that the astrocyte cultures are largely astrocytic and have undergone appropriate lineage restriction.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Study design and conductown data

    A data QC analysis was performed to assess internal standards, injection order effects, retention time variability, and variability of biological lipids.

    “Prior to data analysis, a data QC analysis was performed using a custom R Markdown document to assess the response from internal standards within samples and the pooled QC, injection order effects, retention time variability, and variability of biological lipids.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    Reduced NFIX levels in APOE3-Ch astrocytes suggest these cells may be less mature than WT astrocytes, indicating that the APOE3-Ch variant may impede normal astrocyte maturation.

    “Its reduced levels in APOE3‐Ch astrocytes suggest that these cells may be less mature than the control line, indicating that the APOE3‐Ch variant may impede normal astrocyte maturation.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: NFIX plays a critical role in astrocyte differentiation and maturation.

  • May combine two claims.

    Interpretationreasoning

    Transcriptomic upregulation of endocytic and cell projection pathways in APOE3-Ch astrocytes aligns with these findings, as these pathways likely enhance the cells' ability to internalize and degrade tau.

    “The transcriptomic upregulation of endocytic and cell projection pathways in APOE3‐Ch astrocytes aligns with these findings, as these pathways likely enhance the cells’ ability to internalize and degrade tau.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    LRP1 can form complexes with HSPGs, allowing ligands such as APOE to either bind directly to the LRP1-HSPG complex or initially interact with HSPGs before being transferred to LRP1 for endocytosis.

    “Research indicates that LRP1 can form complexes with HSPGs, allowing ligands such as APOE to either bind directly to the LRP1–HSPG complex or initially interact with HSPGs before being transferred to LRP1 for endocytosis. 45”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [45] Ji ZS, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E‐enriched remnant lipoproteins by cultured cells. J Biol Chem. 1993; 268: 10160‐ 10167. doi: 10.1016/S0021-9258(18)82186-X 7683668 source

  • May combine two claims.

    Interpretationreasoning

    These findings align with mechanisms reported in APOE3-Ch myeloid cells and suggest APOE3-Ch promotes tau clearance through parallel, yet cell type-specific, mechanisms.

    “These findings align with the mechanisms reported in APOE3‐Ch myeloid cells and suggest that APOE3‐Ch promotes tau clearance through parallel, yet cell type–specific, mechanisms.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationreasoning

    For apoE secretion, our use of a commercially validated ELISA kit with high sensitivity versus Murakami et al.'s custom assay may account for divergent findings.

    “For apoE secretion, we used a commercially validated ELISA kit with high sensitivity, while Murakami et al. used a custom assay that may be more variable. Differences in assay sensitivity and detection thresholds could account for the divergent findings.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Study design and conductown data

    Low expression of AQP4 in our astrocytes may suggest incomplete maturation, which could affect the generalizability of our findings.

    “For example, the low expression of AQP4 in our astrocytes may suggest incomplete maturation, which could affect the generalizability of our findings.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Murakami et al. reported no genotype-dependent differences in lipid droplet accumulation or apoE secretion in similarly differentiated iPSC-derived APOE3-Ch astrocytes.

    “Our results differ from those of Murakami et al., 37 who used similarly differentiated iPSC‐derived APOE3‐Ch astrocytes but reported no genotype‐dependent differences in lipid droplet accumulation or apoE secretion.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [37] Murakami R, Watanabe H, Hashimoto H, et al. Inhibitory roles of apolipoprotein E Christchurch astrocytes in curbing tau propagation using human pluripotent stem cell‐derived models. J Neurosci. 2024; 44: e1709232024. doi: 10.1523/JNEUROSCI.1709-23.2024 38649269 PMC11170944 source

  • May combine two claims.

    Interpretationreasoning

    While APOE3-Ch helps clear tau and reduce neurotoxic lipids, it may also impair normal lipid metabolism, potentially leading to long-term vulnerabilities in astrocyte-neuron metabolic coupling.

    “While the variant helps clear tau and reduce neurotoxic lipids, it may also impair normal lipid metabolism, potentially leading to long‐term vulnerabilities in astrocyte–neuron metabolic coupling.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    APOE3-Ch astrocytes may offer protection through two mechanisms: enhanced tau clearance and reduced harmful lipid levels.

    “Unlike the APOE ε4 variant, which has been associated with both impaired lipid metabolism and tau‐induced neurotoxicity, APOE3‐Ch astrocytes may offer protection through two mechanisms: enhanced tau clearance and reduced harmful lipid levels.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Chen et al. demonstrated that APOE3-Ch myeloid cells have significantly enhanced uptake of tau fibrils-mediated by both HSPGs and LRP1-along with increased degradation and reduced tau release after phagocytosis, suggesting a cell-autonomous protective role for APOE3-Ch in limiting tau spread.

    “Notably, their analysis of APOE3‐Ch myeloid cells demonstrated significantly enhanced uptake of tau fibrils—mediated by both HSPGs and LRP1—along with increased degradation and reduced tau release after phagocytosis, suggesting a cell‐autonomous, protective role for APOE3‐Ch in limiting tau spread.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [8] Chen Y, Song S, Parhizkar S, et al. APOE3ch alters microglial response and suppresses Aβ‐induced tau seeding and spread. Cell. 2024; 187: 428‐ 445.e20. doi: 10.1016/j.cell.2023.11.029 38086389 PMC10842861 source

  • May combine two claims.

    Interpretationown data

    Lysosomal degradation in APOE3-Ch astrocytes occurs more rapidly, leading to enhanced tau clearance and preventing accumulation of tau oligomers.

    “Lysosomal degradation in APOE3‐Ch astrocytes occurs more rapidly, leading to enhanced tau clearance and preventing the accumulation of tau oligomers.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Collectively, these studies support a model in which APOE3-Ch confers neuroprotection through coordinated, multicellular actions that enhance tau degradation and reduce extracellular tau propagation.

    “Collectively, these studies support a model in which APOE3‐Ch confers neuroprotection through coordinated, multicellular actions that enhance tau degradation and reduce extracellular tau propagation.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Interpretationreasoning

    The discrepancy with Murakami et al. may stem from technical differences, including our use of 20 μM OA versus their 200 μM OA, which may have saturated lipid storage pathways and masked subtle genotype-specific effects.

    “In our lipid loading assay, we used a moderate dose of 20 µM OA, whereas Murakami et al. used a higher dose of 200 µM. The higher OA concentration may have saturated lipid storage pathways, masking subtle genotype‐specific effects.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationreasoning

    By scavenging tau oligomers more effectively, APOE3-Ch astrocytes may prevent the spread of tau pathology and mitigate neurotoxicity.

    “By scavenging tau oligomers more effectively, APOE3‐Ch astrocytes may prevent the spread of tau pathology and mitigate neurotoxicity.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationown data

    While APOE ε4 impairs astrocytic function and exacerbates tau toxicity, APOE3-Ch astrocytes confer protection by enhancing tau clearance via HSPG- and LRP1-mediated pathways.

    “While APOE ε4 impairs astrocytic function and exacerbates tau toxicity, our findings suggest that APOE3‐Ch astrocytes confer protection by enhancing tau clearance via HSPG‐ and LRP1‐mediated pathways.”
    Quote in the paperSubstantial claim
65 of 65

  • The paper relies on this without support.

    The two APOE3-Ch iPSC lines (1262 and 1264) are equivalent and can be combined to represent a single genotype.

    “Differential expression analysis was conducted with the DESeq2 pipeline, which combines the two APOE3‐Ch lines to represent a single genotype and compares phenotypic differences between genotypes.”

  • The paper relies on this without support.

    iPSC-derived astrocytes recapitulate the relevant properties of human astrocytes in vivo.

    “human iPSC (hiPSC)–derived astrocytes from a WT line and two lines homozygous for the APOE3‐Ch variant were used.”

  • The paper relies on this without support.

    The 2N4R-P301L tau oligomers used are representative of pathological tau species in AD.

    “To prepare tau oligomers, monomeric 2N4R‐P301L tau protein was aggregated following a previously published protocol.”

  • The paper relies on this without support.

    The WT line (KOLF2.1J) is a valid control for APOE3-Ch lines.

    “hiPSC lines, including a WT parental line (KOLF2.1J, Cat. No. JIPSC1000) and two lines homozygous for the APOE3‐Ch mutation (denoted as 1262 and 1264, Cat. No. JIPSC1262 and JIPSC1264), were obtained from The Jackson Laboratory.”

  • The paper relies on this without support.

    The mechanisms by which APOE3-Ch confers protection against AD are poorly understood.

    “However, the underlying mechanisms of protection remain poorly understood.”

  • The paper relies on this without support.

    NFIX plays a critical role in astrocyte differentiation and maturation.

    “NFIX plays a critical role in astrocyte differentiation and maturation.”

  • The paper relies on this without support.

    SGMS1 and SGMS2 convert ceramides to sphingomyelin.

    “Specifically, SGMS1 and SGMS2, which convert Cers to sphingomyelin, were upregulated.”

  • The paper relies on this without support.

    ASAH1 and ACER1 convert ceramides to sphingosine.

    “ASAH1 and ACER1 are responsible for converting Cers to sphingosine, while SPHK1 phosphorylates sphingosine to form sphingosine‐1‐phosphate (S1P), potentially further reducing ceramide levels by diverting sphingosine into the S1P pathway.”

  • The paper relies on this without support.

    SPHK1 phosphorylates sphingosine to form sphingosine-1-phosphate.

    “ASAH1 and ACER1 are responsible for converting Cers to sphingosine, while SPHK1 phosphorylates sphingosine to form sphingosine‐1‐phosphate (S1P), potentially further reducing ceramide levels by diverting sphingosine into the S1P pathway.”

  • The paper relies on this without support.

    Heparin inhibits tau uptake by binding to HSPGs.

    “To explore the mechanisms underlying tau uptake in astrocytes, we conducted competition assays using heparin, which inhibits tau uptake by binding to HSPGs (Figure 3D).”

  • The paper relies on this without support.

    RAP is an LRP1 antagonist.

    “We also assessed the role of LRP1 in tau uptake using RAP, an LRP1 antagonist (Figure 3E).”

  • The paper relies on this without support.

    The effects of APOE3-Ch on CNS lipid metabolism remain unclear.

    “However, the effects of APOE3‐Ch on CNS lipid metabolism remain unclear.”
12 of 12

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Heparin is described as washed out and as co-incubated with tau

    Major

    The methods say heparin was washed away before tau was added, but the results describe 100 μg/mL heparin as co-incubated with tau. These are different competition-assay conditions.

  • Five biological replicates conflict with stated triplicate-or-quadruplicate design

    Minor

    The methods state that all experiments used biological triplicates or quadruplicates, but the lipid-droplet quantification caption reports five biological replicates.

  • Polar-lipid results cite panels assigned to neutral lipids

    Minor

    The polar-lipid discussion points to Figure 2B,C, but the Figure 2 caption identifies B as triacylglycerol unsaturation and C as a heatmap of differentially abundant lipids, not the cited polar-lipid panels.

3 of 3

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Tian, X., Rivera, E. K., Hwang, I., Nikitina, A. A., Smith, J. A., Cho, Y. J., Sala‐Jarque, J., DuBose, A., Andriola, C., Gollan‐Myers, T., & Kosik, K. S.
Affiliations
University of California, Santa Barbara (US)
Corresponding author
Kosik, Kenneth S.
ORCID
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2025-09
Volume
21
Issue
9
Pages
e70589-e70589
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1002/alz.70589
PMC
PMC12444642
OpenAlex
W4414333016
Semantic Scholar
8f0bbce7585fe39b2dbaa69f2955d8f0ba766251
Cited by
7
References
48
Citations by year
2026: 5 · 2025: 2
FWCI
4.50
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc-nd)
Funders
National Institutes of Health (1RF1AG062479)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease
MeSH terms
Alzheimer Disease, Astrocytes, Homozygote, Humans, tau Proteins, Lipid Metabolism, Apolipoprotein E3, Induced Pluripotent Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-31.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-31.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review